[
  {
    "ts": null,
    "headline": "Ametek Inc. stock underperforms Thursday when compared to competitors despite daily gains",
    "summary": "Ametek Inc. stock underperforms Thursday when compared to competitors despite daily gains",
    "url": "https://finnhub.io/api/news?id=494bb920dc2647dd01617be33f4eff6d62256adf8ed12c25df8daa7ffebfa095",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750956780,
      "headline": "Ametek Inc. stock underperforms Thursday when compared to competitors despite daily gains",
      "id": 135664427,
      "image": "",
      "related": "AME",
      "source": "MarketWatch",
      "summary": "Ametek Inc. stock underperforms Thursday when compared to competitors despite daily gains",
      "url": "https://finnhub.io/api/news?id=494bb920dc2647dd01617be33f4eff6d62256adf8ed12c25df8daa7ffebfa095"
    }
  },
  {
    "ts": null,
    "headline": "The Top 5 Analyst Questions From AMETEK’s Q1 Earnings Call",
    "summary": "AMETEK’s first quarter saw sales remain flat year on year, missing Wall Street’s revenue expectations, though adjusted earnings per share came in ahead of consensus. Management attributed steady operational performance to robust margin expansion, strong order growth, and improved free cash flow generation. CEO Dave Zapico highlighted that orders increased across most segments, particularly within the Paragon Medical business, which saw a sharp recovery in demand after a period of customer destoc",
    "url": "https://finnhub.io/api/news?id=56bb76a4e75a85a2956b38721cbdd0658ffc97f0b73c3bd3a22594e6d1b78648",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750921162,
      "headline": "The Top 5 Analyst Questions From AMETEK’s Q1 Earnings Call",
      "id": 135558881,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AME",
      "source": "Yahoo",
      "summary": "AMETEK’s first quarter saw sales remain flat year on year, missing Wall Street’s revenue expectations, though adjusted earnings per share came in ahead of consensus. Management attributed steady operational performance to robust margin expansion, strong order growth, and improved free cash flow generation. CEO Dave Zapico highlighted that orders increased across most segments, particularly within the Paragon Medical business, which saw a sharp recovery in demand after a period of customer destoc",
      "url": "https://finnhub.io/api/news?id=56bb76a4e75a85a2956b38721cbdd0658ffc97f0b73c3bd3a22594e6d1b78648"
    }
  }
]